Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Filing of Class Action Lawsuit in Canada over Alleged Xarelto Bleeding Side Effects

Share Article

The Firm is representing numerous plaintiffs who have filed Xarelto lawsuits in U.S. courts, all of which put forth similar allegations regarding the drug’s association with uncontrollable internal bleeding.

Free Case Review
Our Firm is representing a number of U.S. Xarelto plaintiffs who have cases pending in federal court. We are not surprised that Canada has now seen a similar filing, as the bleeding complications allegedly related to Xarelto are quite serious.

A recent report from the Calgary Herald indicates that a Xarleto class action lawsuit (http://www.xareltolawsuit2015.com/) has been filed in Alberta, Canada on behalf of individuals who allegedly experienced uncontrollable bleeding due to their use of the blood thinner. Among other things, the Canadian lawsuit alleges that Xarelto has been implicated in more than 1,000 injuries in the country, including 12 deaths. The Statement of Claim also accuses the drug’s manufacturers of negligence in their marketing of Xarelto, the Herald reported.*

According to court documents, more than 200 Xarelto lawsuits have also been filed in U.S. courts that put forth similar allegations. The majority of those cases are currently pending in a federal multidistrict litigation underway in U.S. District Court, Eastern District of West Virginia.( In Re: Xarelto Products Liability Litigation, No. 2592)

“Our Firm is representing a number of U.S. Xarelto plaintiffs who have cases pending in federal court. We are not surprised that Canada has now seen a similar filing, as the bleeding complications allegedly related to Xarelto are quite serious, and can be life-threatening,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free, no-obligation legal reviews to individuals who allegedly suffered serious injuries from Xarelto, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.

Xarelto Litigation
Xarelto was first cleared for sale in the U.S. by the Food & Drug Administration (FDA) in 2011. The blood thinner's approved uses now include the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like any anticoagulant, Xarelto can sometimes causes internal bleeding. However, there is currently no approved antidote for reversing Xarelto bleeding.**

According to court documents, the multidistrict litigation established in the Eastern District of Louisiana was created in December 2014 to allow all Xarelto lawsuits filed in U.S. federal courts to undergo coordinated pretrial proceedings. Among other things, plaintiffs claim that the medication was wrongly marketed as an improvement over warfarin, a blood thinner that has been in use for decades. The lawsuits point out that unlike Xarelto, bleeding associated with warfarin can be stopped via the administration of vitamin K. The complaints further note that during its first full year on the market, Xarelto was named in 2,081 adverse event reports submitted to the FDA, including at least 151 deaths. By contrast, warfarin was named in only 861 adverse event reports, including 56 fatalities, during the same period.***

Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.

*calgarysun.com/2015/02/14/calgary-class-action-lawsuit-against-bayer-alleges-negligence-over-xarelto-anticoagulant-drug, Calgarly Sun, February 13, 2015
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
***ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website